Navigation Links
Make or break time for osteoporosis treatment
Date:3/10/2008

Women who do not comply with treatment instructions for osteoporosis or who do not respond to treatment are more likely to suffer further fractures, which seriously affects their quality of life. There is an urgent need to provide support to these patients and address their issues when new therapies are assessed and new treatment guidelines drawn up, according to lead researcher Professor Cyrus Cooper from the MRC Epidemiology Resource Centre, University of Southampton, in the UK. His findings (1) will be published in the April issue of Osteoporosis International, a Springer journal.

Osteoporosis is an increasing global health problem and currently available therapies have been shown to reduce the risk of fragility fractures in postmenopausal women. Most patients gain bone mineral density within a year of treatment. However, surveys of osteoporotic patients show that compliance to treatment is low in practice, and up to 50% of patients stop their treatment within a year due in part to side-effects. In addition, clinical trials show that osteoporotic fractures have physical, psychological and social implications that can seriously affect patients quality of life.

Cooper and colleagues study, the Observational Study of Severe Osteoporosis (OSSO)*, looked at the number of fractures suffered by women who did not respond to drug therapy, and how treatment failure affected their health-related quality of life. A total of 1,885 70-year-old women with established osteoporosis and inadequate clinical response to osteoporosis drug therapy were assessed over a year. The researchers used a combination of two questionnaires to measure their quality of life at the start of the study, and then after six months and after a year. Inadequate clinical response to osteoporosis drug therapy is defined as either a fragility fracture despite therapy for one year, or discontinued drug treatment due to adverse effects and/or noncompliance.

A total of 209 fr
'/>"/>

Contact: Joan Robinson
joan.robinson@springer.com
49-622-148-78130
Springer
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Brain imaging reveals breakdown of normal emotional processing
2. Treating diabetes during pregnancy can break link to childhood obesity
3. Breaking Up Is Not So Hard to Do
4. Bioniche Responds to Australian Equine Influenza Outbreak
5. IVCC launches groundbreaking insecticide projects with Bayer and Syngenta
6. PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County
7. On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack
8. Dermatologists identify North Texas leishmaniasis outbreak
9. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam
10. Right breakfast bread keeps blood sugar in check all day
11. Prime Access Creates Groundbreaking Ads Targeting Urban Teens for the White Houses National Youth Anti-Drug Media Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)...stained Energy Enhancing Supplement, BOCA RATON, ...sed,nutritional supplement manufacturer, introduce...., Glyc,n Go, is the first and only chewable form...t, and the effects that it has on the,energy syste...trainers,around the globe., In clinical trials, t...
(Date:10/13/2008)...wswire/ -- NeoVista, Inc., presented,yesterday the...l,brachytherapy device on choroidal neovascular le...tina Specialist,s (ASRS) 26th Annual Meeting. The,...S., of The Methodist,Hospital, Houston, Texas, dem...y and ocular coherence tomography (OCT) in many pa...
(Date:10/13/2008)...taJobs.com and numerous newspaper affiliates have ...com . AtlantaJobs.com is the newest online job bo...bseekers in the metro Atlanta area. , ...-- AtlantaJobs.com and numerous newspaper affili...aJobs.com is the newest online job board dedicate...
(Date:10/12/2008)... Five neonatology fellows have been awarded grants...e area of follow-up care of the premature infant a...ts, which underscore MedImmune,s commitment to exp...ovide each recipient,s institution a $35,000 grant...recipients were acknowledged on Sunday, October 12...
Breaking Medicine News(10 mins):Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3Health News:Atlanta Area Job Board Launches New Local Job Board to Connect Local Employers and Jobseekers 2Health News:MedImmune grants 5 new fellowships to help expand premature infant follow-up care research 2
...ts. Now, BT Offices and Vans will sport an anti-sm...ng is banned in the BT premises as well as in the ...tantly, this move might encourage “anti-smoking” i...n. The anti-smoking activists have seconded this ...
... improvement with Viagra could now benefit from st...ighlight the use of statins for management of endo...m erectile dysfunction. The result of this small, ...ennsylvania researchers is published in the Journa...
... Railways to take off chicken and egg related dish...n issued to all the Zonal Railways and other railw...fficial quoted that such a decision was taken upon...rest. As the disease itself is highly contagious,...
...construct a world-class cancer hospital and resear...come up at Rajarhat,// at the cost of Rs. 1.2 bill... Centre (TMC) would come up on a 10-acre plot, Wes...tacharjee and Tata Group chairman Ratan Tata said,...
Other Medicine News:Health News:Statins For Erectile Dysfunction- An Alternative To Viagra? 2
(Date:10/12/2008)...and WASHINGTON, Oct. 12 /- ...announced results from an analysis,of nearly 7,500..., which,are designed to confirm the performance of...nary Stent System in real-world practice. The,two-...t reduced clinical,restenosis in patients with dia...
(Date:10/10/2008)...Mich., Oct. 10 /- Diplomat Specialty,...s selected Diplomat,Specialty Pharmacy to be one o..., national Therapy Optimization Study for Multiple...OP MS study, is to examine the benefits of a,speci...ance, adherence and,patient outcomes. Targeted pat...
(Date:10/10/2008)..., Oct. 10 /- Inverness Medi...vider of near-patient,diagnostics, monitoring and ...n Ki-moon, the Secretary-General of the United Nat...eventeen of the world,s leading,research-based and...Inverness, together with senior officials from the...
(Date:10/10/2008)...lif., Oct. 10 /- TriReme Medical Inc.... to affix the CE (Conformite,Europeenne) marking a...y,Stent System, a unique main vessel stent system ...urcations., Representing the next generation in b...tential use in a quarter of the 2.2 million,angiop...
Breaking Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2Leading Childrens Hospital Utilizes MEDais Solutions to Deliver Outstanding Care 4025 1Leading Childrens Hospital Utilizes MEDais Solutions to Deliver Outstanding Care 4025 2Nventa updates progress of cervical dysplasia trial with new HspE7 1339 1Nventa updates progress of cervical dysplasia trial with new HspE7 1339 2Nventa updates progress of cervical dysplasia trial with new HspE7 1339 3Nventa updates progress of cervical dysplasia trial with new HspE7 1339 4Nventa updates progress of cervical dysplasia trial with new HspE7 1339 5Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 1Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 3FDA Panel Mulls Ban on Kids Cold Medicines 4019 1FDA Panel Mulls Ban on Kids Cold Medicines 4019 2FDA Panel Mulls Ban on Kids Cold Medicines 4019 3FDA Panel Mulls Ban on Kids Cold Medicines 4019 4
... Data presented at the 11th International Myeloma ... activity of perifosine in,combination with bortez...asone, in patients with relapsed/refractory multip... relapsed/refractory,Waldenstrom,s macroglobulinem... -- Keryx,Biopharmaceuticals, Inc. today announced...
... IRVING, Texas--(BUSINESS WIRE)--Jun 29, 2007 - Re...entation of new,preclinical data showing their lea...A 402, is effective at protecting against,common t... This,data was presented at the annual meeting of ...n Cancer (MASSC) in St Gallen,Switzerland., Reata...
Other Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 2RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 3
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: